Get started
Author

Xiaoguang Wang

ORCID: 0000-0002-8185-0319
Observed ORCID: 0000-0002-8185-0319
OpenAlex ID: A5102734922
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
2020 · Xiaoguang Wang, Brittany C. Waschke, et al. · Protein & Cell · 95
PDF
T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
2023 · Vi Lam, Carly Roleder, et al. · Molecular Cancer Therapeutics · 17
PDF
Data from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
2023 · Vi Lam, Carly Roleder, et al. · 1
Supplementary Figure S8 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
2026 · Xiaoguang Wang, Varun N. Kapoor, et al.
Supplementary Table S2 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
2026 · Xiaoguang Wang, Varun N. Kapoor, et al.
Supplementary Figure S5 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
2026 · Xiaoguang Wang, Varun N. Kapoor, et al.
Supplementary Figure S7 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
2026 · Xiaoguang Wang, Varun N. Kapoor, et al.
Supplementary Figure S4 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
2026 · Xiaoguang Wang, Varun N. Kapoor, et al.
Supplementary Figure S1 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
2026 · Xiaoguang Wang, Varun N. Kapoor, et al.
Supplementary Table S3 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
2026 · Xiaoguang Wang, Varun N. Kapoor, et al.
Supplementary Table S1 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
2026 · Xiaoguang Wang, Varun N. Kapoor, et al.
Supplementary Figure S2 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
2026 · Xiaoguang Wang, Varun N. Kapoor, et al.
Supplementary Figure S3 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
2026 · Xiaoguang Wang, Varun N. Kapoor, et al.
Supplementary Figure S6 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
2026 · Xiaoguang Wang, Varun N. Kapoor, et al.
Data from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
2026 · Xiaoguang Wang, Varun N. Kapoor, et al.
Figure S3 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
2025 · Vi Lam, Carly Roleder, et al.
Table S2 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
2025 · Vi Lam, Carly Roleder, et al.
Table S2 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024 · Vi Lam, Carly Roleder, et al.
Table S1 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024 · Vi Lam, Carly Roleder, et al.
Figure S1 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024 · Vi Lam, Carly Roleder, et al.
Figure S2 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024 · Vi Lam, Carly Roleder, et al.
Data from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024 · Vi Lam, Carly Roleder, et al.
Figure S4 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024 · Vi Lam, Carly Roleder, et al.
Figure S2 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024 · Vi Lam, Carly Roleder, et al.
Supplementary Data Methods from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024 · Vi Lam, Carly Roleder, et al.
Works count: 62
Citation count: 113
H-index: 2
I10-index: 2
Year
Topic
Type